Clinical Trial Detail

NCT ID NCT02576275
Title A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)
Recruitment Withdrawn
Gender both
Phase Phase III
Variant Requirements No
Sponsors Infinity Pharmaceuticals, Inc.
Indications

marginal zone B-cell lymphoma

follicular lymphoma

CLL/SLL

Therapies

Bendamustine + Rituximab

Duvelisib

Age Groups: adult

No variant requirements are available.